Navigation Links
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008 

    First-line trial currently shows median overall survival of 27.5 months
     for OGX-011 in combination with docetaxel and prednisone and a 16.9
         months overall survival for docetaxel and prednisone alone.

       Achievement of survival benefit milestone results in release of
                   all remaining escrowed shares of OGXI.

BOTHELL, WA and VANCOUVER, Dec. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.

Based on the median overall survival advantage, the Board of Directors of OncoGenex Pharmaceuticals has approved the release of all of the remaining shares held in escrow pursuant to agreements related to Sonus Pharmaceuticals' merger with OncoGenex Technologies described in its Proxy Statement filed with the SEC on July 3, 2008. The escrow agreements provided for the release of 50% of the original number of shares held in escrow following the demonstration of at least a two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone shares have now been released from escrow; as of December 3, 2008 there are 5,513,643 shares outstanding.

The trial was conducted and data were analyzed by the National Cancer Institute of Canada, Clinical Trials Group and was supported by a grant from the NCI-C
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
6. NicOx Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
7. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
10. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
11. Jellyfish Protein Shows Potential to Help With Memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MO BIO Laboratories, Inc., the leader ... nucleic acid purification, announces the launch of the ... pure protein from all soil types. This expansion ... th anniversary of the company and showcases ... http://photos.prnewswire.com/prnh/20130619/LA32633 ) The NoviPure™ ...
(Date:6/19/2013)... Bayer CropScience will honor Illinois beekeeper ... Community Leadership Award. The award will be announced at ... Washington, D.C., an event where supporters of pollinator health ... supply. , The Bayer Bee Care Community Leadership ... the honey bee colony to benefit their community. Applicants ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
Breaking Biology Technology:MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2
... Orlando, I spoke at the well-attended BICSI Conference . While ... PEAK 10's data centers to get a first-hand view of ... doing some online research, and I figured I would have a ... article because data centers have become an issue. , ...
... - Higher operating expenses offset strong quarterly revenue as ... media communications technology, reported a net loss of $1.4 million ... fiscal year 2007. , ,The quarterly net loss was ... share net loss in the same quarter of 2006. The ...
... keynote speech given to open the recent DEMO 2007 Conference ... be surprised by the energy in this room today, and ... an exciting shift in the information technology market. As computing ... ,Quite honestly, we have struggled to find a name for ...
Cached Biology Technology:Data centers: Blowing smoke and raising red flags 2Data centers: Blowing smoke and raising red flags 3Data centers: Blowing smoke and raising red flags 4Data centers: Blowing smoke and raising red flags 5Data centers: Blowing smoke and raising red flags 6Age of empowered individuals: People power behind robust computing 2Age of empowered individuals: People power behind robust computing 3Age of empowered individuals: People power behind robust computing 4Age of empowered individuals: People power behind robust computing 5
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... University, sophisticated computational models and advances in graphical ... interplay between genomic data, virus structure and the ... for replication. , "We hope that ... researchers alter virus assembly, leaving viruses unable to ... of the scientific paper describing the technique, published ...
(Date:6/18/2013)... Institutes of Health has awarded $12.7 million to ... of pharmaceutical industry compounds to explore new treatments ... disease, Duchenne muscular dystrophy and schizophrenia. The collaborative ... Existing Molecules, is led by the National Center ... the NIH Common Fund. , The process of ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... been named as one of the 2008 Environmental Scientists ... His half-brother, biologist Jules Blais, is the other winner ... prestigious in the environmental sciences. The prize recognizes the ... Smol is series editor of the Springer ...
... 2 BIO-key International,Inc. (OTC Bulletin Board: BKYI), ... identification solutions, today announced that it,has been awarded ... with a large multi-national technology company. BIO-key will,license ... be used on,multiple, large international and domestic opportunities., ...
... WI, JUNE 2, 2008-- An understanding how environmental ... transport and fate of agricultural chemicals in the ... degradation of surface and ground waters from past, ... has been conducted at field or smaller scales, ...
Cached Biology News:BIO-key(R) Awarded $2 Million Biometric Contract by Multi-National Company 2Holistic understanding: Ag chemicals in the environment 2
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: